Healthcare · Biotechnology
Price
$1.50
Market Cap
$14.1M
Employees
12
Beta
0.33
Avg Volume
53,067
CEO
Imran Alibhai
Business Description
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Business History
Price Overview
Last updated: Jun 27, 2026 8:03am (just now)$1.50
-0.86 (-36.44%)
Day Range
$1.50 – $2.48
52-Week Range
$1.50 – $43.65
50-Day MA
$3.20
200-Day MA
$7.75
Volume
1,714,461.00
Analyst Price Targets
Low
$3.00
Consensus
$6.00
High
$9.00
(6 analysts)
Share Structure
Outstanding
9,381,344.00
Float
6,081,481.00
Free Float
64.8%
Normal free float
— 64.8% of shares trade freely, ~35.2% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (6.1M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.61
Stock Price: $1.50
EPS (Diluted): -2.46
EPS (Diluted): -2.46
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.52
Stock Price: $1.50
Total Equity: $20.95M
Shares: 7,783,182
Total Equity: $20.95M
Shares: 7,783,182
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.37
Market Cap: $14.07M
Total Debt: $0.00
Cash: $20.73M
EBITDA: -$18.12M
Total Debt: $0.00
Cash: $20.73M
EBITDA: -$18.12M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$11.4M
Market Cap: $14.07M
Total Debt: $0.00
Cash: $20.73M
Total Debt: $0.00
Cash: $20.73M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.50
Revenue: $0.00
Shares: 7,783,182
Revenue: $0.00
Shares: 7,783,182
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$95,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$26.75M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$18.21M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-64.2%
Net Income: -$18.21M
Total Equity: $20.95M
Total Equity: $20.95M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-200.6%
Operating Income: -$26.75M
Tax Rate: 0.0%
Equity: $20.95M
Total Debt: $0.00
Cash: $20.73M
Tax Rate: 0.0%
Equity: $20.95M
Total Debt: $0.00
Cash: $20.73M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.86
Current Assets: $31.54M
Current Liabilities: $11.04M
Current Liabilities: $11.04M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $20.95M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $20.95M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 7,783,182
Shares: 7,783,182
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.69
Total Equity: $20.95M
Shares: 7,783,182
Shares: 7,783,182
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.02
Operating CF: -$23.50M
CapEx: $0.00
Shares: 7,783,182
CapEx: $0.00
Shares: 7,783,182
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.50
Stock Price: $1.50
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$18.21M
Net Income: -$18.21M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares TVRD against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 11:40pm (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $23.0M | $41.9M | $21.0M | $7.1M | $0 |
| Cost of Revenue | $1.6M | $7.5M | $6.4M | $812,000 | $95,000 |
| Gross Profit | $21.5M | $34.4M | $14.5M | $6.3M | $-95,000 |
| Operating Expenses | $110.6M | $121.9M | $136.0M | $62.1M | $26.7M |
| Operating Income | -$89.1M | -$87.5M | -$121.5M | -$55.8M | -$26.7M |
| Net Income | -$88.4M | -$85.5M | -$118.5M | -$70.9M | -$18.2M |
| EBITDA | -$86.9M | -$83.8M | -$117.7M | -$62.6M | -$18.1M |
| EPS | $-62.77 | $-2.20 | $-1.85 | $-46.59 | $-2.46 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 11:40pm (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $13.5M | $21.5M | $22.9M | $37.9M | $20.7M |
| Total Current Assets | $173.3M | $44.1M | $26.2M | $43.8M | $31.5M |
| Total Assets | $247.1M | $45.1M | $27.0M | $43.8M | $32.1M |
| Current Liabilities | $17.6M | $4.3M | $3.3M | $4.0M | $11.0M |
| Long-Term Debt | $0 | $0 | $0 | $44.4M | $0 |
| Total Liabilities | $19.5M | $90.1M | $89.1M | $48.4M | $11.1M |
| Total Equity | $227.5M | -$45.1M | -$62.1M | -$4.6M | $20.9M |
| Retained Earnings | -$480.8M | -$45.5M | -$62.8M | -$755.6M | -$110.5M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 11:40pm (8h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$60.1M | -$17.9M | -$21.0M | -$60.9M | -$23.5M |
| Capital Expenditure | $-39,000 | $-50,000 | -$2.4M | -$1.0M | $0 |
| Free Cash Flow | -$60.1M | -$17.9M | -$21.0M | -$62.0M | -$23.5M |
| Acquisitions (net) | $70,000 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$18.2M | -$39.9M | $1.4M | -$14.3M | -$10.9M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:40pm (8h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 |
$1.2M $1.2M – $1.2M
|
$11.6M $11.6M – $11.6M
|
$29.4M $29.4M – $29.4M
|
| EBITDA | $0 |
$-700,000 $-700,000 – $-700,000
|
-$7.0M -$7.0M – -$7.0M
|
-$17.7M -$17.7M – -$17.7M
|
| Net Income |
-$23.9M -$34.2M – -$13.6M
|
-$25.7M -$49.8M – -$1.6M
|
-$21.2M -$21.2M – -$21.2M
|
-$15.2M -$15.2M – -$15.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 11:40pm (8h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +81.8% | -49.9% | -66.0% | -100.0% |
| Gross Profit Growth | +60.0% | -57.7% | -56.5% | -101.5% |
| Operating Income Growth | +1.7% | -38.8% | +54.1% | +52.0% |
| Net Income Growth | +3.4% | -38.7% | +40.2% | +74.3% |
| EBITDA Growth | +3.5% | -40.4% | +46.8% | +71.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Shiff Susan Ph.D. | A-Award | 6,000.00 | $2.78 | $16,680 |
| 2026-06-09 | Smith Cynthia | A-Award | 6,000.00 | $2.78 | $16,680 |
| 2026-06-09 | Shah Sujal | A-Award | 6,000.00 | $2.78 | $16,680 |
| 2026-06-09 | HALL WALLACE L JR | A-Award | 6,000.00 | $2.78 | $16,680 |
| 2026-06-09 | WYZGA MICHAEL S | A-Award | 6,000.00 | $2.78 | $16,680 |
| 2026-01-29 | O'Brien Stephen Paul | A-Award | 15,000.00 | $3.90 | $58,500 |
| 2026-01-29 | Conn Avi Daniel | A-Award | 45,000.00 | $3.90 | $175,500 |
| 2026-01-29 | Kauh John Saewook M.D. | A-Award | 45,000.00 | $3.90 | $175,500 |
| 2026-01-29 | Alibhai Imran Nizamudin | A-Award | 115,000.00 | $3.90 | $448,500 |
| 2025-12-16 | O'Brien Stephen Paul | A-Award | 4,000.00 | $4.20 | $16,800 |
| 2025-12-16 | Kauh John Saewook M.D. | A-Award | 17,500.00 | $4.20 | $73,500 |
| 2025-12-16 | Conn Avi Daniel | A-Award | 17,500.00 | $4.20 | $73,500 |
| 2025-12-16 | Alibhai Imran Nizamudin | A-Award | 47,500.00 | $4.20 | $199,500 |
| 2025-07-07 | Tweardy Samuel David | J-Other | 315,658.00 | $0.00 | $0 |
| 2025-04-15 | HALL WALLACE L JR | A-Award | 202,044.00 | $0.00 | $0 |
| 2025-04-15 | HALL WALLACE L JR | A-Award | 44,712.00 | $0.00 | $0 |
| 2025-04-15 | Wirk Shaheen | A-Award | 263,164.00 | $0.00 | $0 |
| 2025-04-15 | Wirk Shaheen | A-Award | 176,030.00 | $0.00 | $0 |
| 2025-04-15 | Tweardy Samuel David | 0.00 | $0.00 | $0 | |
| 2025-04-17 | Larson Jeffrey Leroy | A-Award | 10,820.00 | $17.04 | $184,373 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TVRD — it's generated by the pipeline (
market-narrative step).
No community reviews yet for TVRD.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30